SEARCH

SEARCH BY CITATION

References

  • 1
    Scandella DH. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin Thromb Hemost 2000; 26: 13742.
  • 2
    Strauss HS, Merler E. Characterization and properties of an inhibitor of factor 8 in the plasma of patients with hemophilia A following repeated transfusions. Blood 1967; 30: 13750.
  • 3
    Capel P, Toppet M, Van Remoortel E, Fondu P. Factor VIII inhibitor in mild haemophilia. Br J Haematol 1986; 62: 7867.
  • 4
    Hoyer LW. Why do so many haemophilia A patients develop an inhibitor? Br J Haematol 1995; 90: 498501.
  • 5
    Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 7626.
  • 6
    Kesteven PJ, Holland LJ, Lawrie AS, Savidge GF. Inhibitor to factor VIII in mild haemophilia. Thromb Haemost 1984; 52: 502.
  • 7
    Peerlinck K, Jacquemin MG, Arnout J, Hoylaerts MF, Gilles JG, Lavend'homme R, Johnson KM, Freson K, Scandella D, Saint-Remy JM, Vermylen J. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999; 93: 226773.
  • 8
    White B, Cotter M, Byrne M, O'Shea E, Smith OP. High responding factor VIII inhibitors in mild haemophilia—is there a link with recent changes in clinical practice? Haemophilia 2000; 6: 1135.
  • 9
    Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000; 85: 713.
  • 10
    Beck P, Giddings JC, Bloom AL. Inhibitor of factor VIII in mild haemophilia. Br J Haematol 1969; 17: 2838.
  • 11
    Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 5948.
  • 12
    Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 1992; 67: 6002.
  • 13
    Strauss HS. Acquired circulating anticoagulants in hemophilia A. N Engl J Med 1969; 281: 86673.
  • 14
    McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 3448.
  • 15
    Lechner K, Ludwig E, Niessner H, Thaler E. Factor VIII inhibitor in a patient with mild hemophilia A. Haemostasis 1972; 1: 26170.
  • 16
    Bovill EG, Burns SL, Golden EA. Factor VIII antibody in a patient with mild haemophilia. Br J Haematol 1985; 61: 3238.
  • 17
    European Study Group of Factor VIII Antibody. Development of factor VIII antibody in haemophilic monozygotic twins. Scand J Haematol 1979; 23: 648.
  • 18
    Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 1158.
  • 19
    Fijnvandraat K, Turenhout EA, Van Den Brink EN, Ten Cate JW, Van Mourik JA, Peters M, Voorberg J. The missense mutation Arg593[RIGHTWARDS ARROW]Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997; 89: 43717.
  • 20
    Hay CR, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A, Teitel J, Mannucci PM, Kasper CK. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75: 259.
  • 21
    Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 14026.
  • 22
    Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE, Peake IR. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 2347.
  • 23
    Crowell EB Jr. A factor VIII inhibitor in a mild hemophiliac. Am J Med Sci 1970; 260: 2613.
  • 24
    Varon D, Martinowitz U. Continuous infusion therapy in haemophilia. Haemophilia 1998; 4: 4315.
  • 25
    Tagariello G, Davoli PG, Gajo GB, De Biasi E, Risato R, Baggio R, Traldi A. Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion. Haemophilia 1999; 5: 42630.
  • 26
    Williams IJ, Abuzenadah A, Winship PR, Preston FE, Dolan G, Wright J, Peake IR, Goodeve AC. Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis. Thromb Haemost 1998; 79: 7236.
  • 27
    Van Den Brink EN, Timmermans SM, Turenhout EA, Bank CM, Fijnvandraat K, Voorberg J, Peters M. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593[RIGHTWARDS ARROW]Cys substitution. Thromb Haemost 1999; 81: 7236.
  • 28
    Thompson AR, Murphy ME, Liu M, Saenko EL, Healey JF, Lollar P, Scandella D. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood 1997; 90: 190210.
  • 29
    Scandella D, Kessler C, Esmon P, Hurst D, Courter S, Gomperts E, Felch M, Prescott R. Epitope specificity and functional characterization of factor VIII inhibitors. Adv Exp Med Biol 1995; 386: 4763.
  • 30
    Knobe KE, Villoutreix BO, Tengborn LI, Petrini P, Ljung RC. Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations. Haemostasis 2000; 30: 26879.
  • 31
    Xie YG, Zheng H, Leggo J, Scully MF, Lillicrap D. A founder factor VIII mutation, valine 2016 to alanine, in a population with an extraordinarily high prevalence of mild hemophilia A. Thromb Haemost 2002; 87: 1789.
  • 32
    Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 23842.
  • 33
    Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82: 5004.
  • 34
    Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 4539.
  • 35
    Kasper CK. Hemophilia Bulletin. Los Angeles: Orthopaedic Hospital, 2002.
  • 36
    Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 9911045.
  • 37
    Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther 1999; 10: 2091107.
  • 38
    Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients—a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 14554.
  • 39
    Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999; 5: 2036.
  • 40
    Baglin T, Beacham E. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Thromb Haemost 1998; 80: 10367.
  • 41
    Dykes AC, Walker ID, Lowe GD, Tait RC. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review. Haemophilia 2001; 7: 1603.
  • 42
    Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 14637.
  • 43
    Puetz JJ, Bouhasin JD. High-titre factor VIII inhibitor in two children with mild haemophilia A. Haemophilia 2001; 7: 2159.
  • 44
    Robbins D, Kulkarni R, Gera R, Scott-Emuakpor AB, Bosma K, Penner JA. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol 2001; 68: 1848.
  • 45
    Shapiro SS. Characterization of factor VIII antibodies. Ann NY Acad Sci 1975; 240: 35061.
  • 46
    Suzuki T, Arai M, Miyasaka S, Watanabe J, Sugimura D, Amano K, Yamagishi T, Kagawa K, Fukue H, Fukutake K. Factor VIII inhibitor developed in a 60-year-old patient with mild hemophilia A after surgery for colon cancer. Int J Hematol 1995; 62: 12732.
  • 47
    Koestenberger M, Raith W, Muntean W. High titre inhibitor after continuous factor VIII administration for surgery in a young infant. Haemophilia 2000; 6: 120.
  • 48
    Vlot AJ, Wittebol S, Strengers PF, Turenhout EA, Voorberg J, Van Den Berg HM, Mauser-Bunschoten EP. Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618[RIGHTWARDS ARROW]Ser mutation responsive to immune tolerance induction and cyclophosphamide. Br J Haematol 2002; 117: 13640.
  • 49
    Liu ML, Nakaya S, Thompson AR. Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses. Thromb Haemost 2002; 87: 2736.
  • 50
    Rosenthal MC. Hemophilia and Hemophiliod Diseases. Chapel Hill: University of North Carolina Press, 2002: 51.